Latest Resmed (ASX:RMD) News

Healthcare shares delivered mixed results as Percheron surged on a leadership change, while ResMed gained on stronger sales and portfolio changes.
Biotech funding, medical-device expansion and new software contracts shaped the week, but several small-cap gaps quickly lost ground.

ResMed Inc. posted a 10% rise in fiscal 2026 revenue to $5.65 billion, bolstered by the acquisition of Noctrix Health and an agreement to sell its MatrixCare business. The company continues to invest in AI-powered digital health solutions amid ongoing patent litigation and a shifting regulatory landscape.

Small-cap resources stocks led the week, while takeover activity and strong company results added to the gains. Wellnex Life more than doubled, but sharp falls in Trek Metals and Ionic Rare Earths showed that positive news did not always bring buyers.

Wellnex led the healthcare market after agreeing to sell Pain Away for up to A$21.3 million. Neuren and Lumos also rose strongly as sales, royalties and product orders improved.

Resmed delivered a strong FY2026 with 10% revenue growth to $5.7 billion, a 17% rise in non-GAAP EPS, and a 10% dividend hike. Strategic moves include selling MatrixCare and acquiring Noctrix Health.

Mining news drove the week, with drilling hits, funding wins and takeover bids pushing several small and mid-cap names sharply higher or lower. The biggest swings came from tin, platinum group metals and copper, while gold M&A in WA stayed at the centre of trading.

ResMed is offloading its MatrixCare business in a $490 million cash deal, reinforcing its strategic pivot towards high-growth sleep and connected care markets. The sale proceeds will fuel shareholder returns and innovation investments.

Biotech price swings were led by Dimerix’s slide, while TrivarX and LTR Pharma surged on clinical and commercial progress. Capital raisings, FDA milestones and first sales kept healthcare investors busy, but several early jumps faded as traders locked in gains.

Resmed delivered a robust Q3 FY2026 with 11% revenue growth, margin expansion, and a 21% jump in non-GAAP EPS, while announcing a new U.S. distribution centre and a $0.60 dividend.

Healthcare stocks split into two stories this week: big names sold off hard, while a few small caps ran on clear news. The biggest moves came from a sharp fall in Pro Medicus and Cochlear, while Noxopharm jumped after a top-tier journal publication.

ResMed Inc has updated the foreign exchange rate for its upcoming dividend payment to Australian CDI holders, impacting the Australian dollar amount payable per share. The dividend remains unfranked and subject to US withholding tax, with a reduced rate available under the US-Australia tax treaty.

A single exploration name blew the doors off the leaderboard, while two well-known uranium plays and a Nevada explorer sank hard. Behind the noise: deals got closer to completion, big raisings reset prices, and several “good news” gaps didn’t survive the week.